P16INK4a immunohistochemistry is a promising biomarker to predict the outcome of low grade cervical intraepithelial neoplasia: Comparison study with HPV genotyping

Journal of Gynecologic Oncology

Volumn 24, Issue 3, 2013, Pages 215-221

  Nishio, Sakiko ^a   Fujii, Takuma ^a,c   Nishio, Hiroshi ^a   Kameyama, Kaori ^a   Saito, Miyuki ^a   Iwata, Takashi ^a   Kubushiro, Kaneyuki ^b   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Cervical intraepithelial neoplasia; Human papillomavirus; Immunohistochemistry; P16INK4a

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; GENOTYPE; HIGH RISK PATIENT; HPV GENOTYPING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PAPILLOMAVIRUS INFECTION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; UTERINE CERVIX CARCINOMA IN SITU;

EID: 84880724957     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2013.24.3.215     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-192.
3. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
4. Nakagawa H, Sugano K, Fujii T, Kubushiro K, Tsukazaki K, Nozawa S. Frequent detection of human papilloma viruses in cervical dysplasia by PCR single-strand DNA-conformational polymorphism analysis. Anticancer Res 2002;22:1655-1660.
5. Fujii T, Tsukazaki K, Kiguchi K, Kubushiro K, Yajima M, Nozawa S. The major E6/E7 transcript of HPV-16 in exfoliated cells from cervical neoplasia patients. Gynecol Oncol 1995;58:210-5.
6. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007;197:340-345.
7. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119:1095-1101.
8. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008;17:2536-2545.
9. Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A 1996;93:4350-4354.
10. Hu L, Guo M, He Z, Thornton J, McDaniel LS, Hughson MD. Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents. Mod Pathol 2005;18:267-273.
11. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
12. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-1748.
13. Omori M, Hashi A, Nakazawa K, Yuminamochi T, Yamane T, Hirata S, et al. Estimation of prognoses for cervical intraepithelial neoplasia 2 by p16INK4a immunoexpression and high-risk HPV in situ hybridization signal types. Am J Clin Pathol 2007;128:208-217.
14. Hariri J, Oster A. The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol 2007;26:223-228.
15. del Pino M, Garcia S, Fuste V, Alonso I, Fuste P, Torne A, et al. Value of p16(INK4a) as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. Am J Obstet Gynecol 2009;201:488.e1-e7.
16. Ozaki S, Zen Y, Inoue M. Biomarker expression in cervical intraepithelial neoplasia: potential progression predictive factors for low-grade lesions. Hum Pathol 2011;42:1007-1012.
17. Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, et al. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study. Int J Cancer 2011;128:2898-2910.
18. Masumoto N, Fujii T, Ishikawa M, Mukai M, Saito M, Iwata T, et al. Papanicolaou tests and molecular analyses using new fluid-based specimen collection technology in 3000 Japanese women. Br J Cancer 2003;88:1883-1888.
19. Fujii T, Saito M, Iwata T, Hirao N, Nishio H, Ohno A, et al. Ancillary testing of liquid-based cytology specimens for identification of patients at high risk of cervical cancer. Virchows Arch 2008;453: 545-555.
20. Sasagawa T, Basha W, Yamazaki H, Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev 2001;10:45-52.
21. Onuki M, Matsumoto K, Satoh T, Oki A, Okada S, Minaguchi T, et al. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 2009;100:1312-1316.
22. Ishikawa M, Fujii T, Saito M, Nindl I, Ono A, Kubushiro K, et al. Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. Int J Gynecol Cancer 2006;16:347-353.
23. Negri G, Vittadello F, Romano F, Kasal A, Rivasi F, Girlando S, et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch 2004;445: 616-620.